Core Viewpoint - The report from CMB International indicates a downward revision of revenue forecasts for CSPC Pharmaceutical Group (01093.HK) for 2025-2027 by 5-8% and net profit forecasts by 16-21%, with a target price adjustment to HKD 7.3. The firm sees both opportunities and risks for the company, maintaining a "Neutral" rating [1]. Group 1: Analyst Ratings - CMB International's latest report assigns a "Neutral" rating to CSPC Pharmaceutical Group with a target price of HKD 7.3 [1]. - In the past 90 days, six investment banks have issued "Buy" ratings for the stock, with an average target price of HKD 11.03 [1][2]. Group 2: Market Position and Financial Metrics - CSPC Pharmaceutical Group has a market capitalization of HKD 88.953 billion, ranking third in the chemical pharmaceutical industry [2]. - Key financial metrics for CSPC Pharmaceutical Group compared to industry averages include: - ROE: 12.07% vs. industry average of -11.38% [3] - Revenue: HKD 25.998 billion vs. industry average of HKD 14.477 billion [3] - Net Profit Margin: 19.39% vs. industry average of -34.83% [3] - Gross Margin: 65.62% vs. industry average of 50.96% [3] - Debt Ratio: 24.21% vs. industry average of 39.81% [3]
交银国际：下调石药集团(01093.HK)目标价至7.3港元 维持“中性”评级